Compare HP Inc (HPQ) vs Johnson & Johnson (JNJ) Price & Performance

HPQ trades at $24.395, down 1.79% on the day, with a bullish technical setup showing strong moving average signals. The stock offers attractive valuation metrics including a P/E of 9.2 and P/S of 0.41, with consistent earnings beats in recent quarters. Recent developments include strategic partnerships with OpenAI and Ferrari, positioning the company for AI PC growth. Cash flow trends show improvement with 2025 net cash flow of $460 million, though revenue has declined from 2022's $63B to $55.3B in 2025.

HPQ presents a value opportunity with strong dividend yield and improving cash flows, but faces headwinds from PC market volatility and competitive pressures. Analyst sentiment is mixed with 29% buy ratings versus 55% hold, suggesting cautious optimism. The stock's near-term performance will depend on AI PC adoption and execution of new strategic partnerships.

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.